ExpreS2ion Biotechnologies - Presentation of half-year 2024 report
You can already now sign up for the event and send in your questions. You don’t have to participate live to send in questions for the event.
ExpreS2ion Biotechnologies is expected to release its 2024 half-year results on 15 August 2024. Later the same day at 10:00, the company’s CEO Bent U. Frandsen and CFO Keith Alexander will take a deeper dive into the results and achievements during the period in an online presentation. The presentation will be followed by a Q&A session.
Ahead of the report, ExpreS2ion Biotechnologies has finalized its capital raise resulting in around SEK 30m in new capital before costs to fund the further advancement in its development plans for ES2B-C001, with near-term milestones including filing the CTA application and obtaining regulatory approval to commence the first-in-human Phase I clinical trial. The progress here and comments about the pipeline could come into focus.
ExpreS2ion Biotechnologies is a Danish pharmaceutical company, which focuses on the development of vaccines through the use of its non-viral Drosophila S2 cells-based expression system.
Disclaimer: HC Andersen Capital receives payment from ExpreS2ion Biotechnologies for a Digital IR/Corporate Visibility subscription agreement. /Michael Friis, 09.38, 8 July 2024.
